Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Kamal MA, Kosloski MP, Lai CH, Partridge MA, Rajadhyaksha M, Kanamaluru V, Bansal A, Shabbir A, Shumel B, Ardeleanu M, Richards SM, Yan H, Xu CR, Rodríguez-Marco A, Xiao J, Khokhar FA, Gherardi G, Babilonia E, Maloney J, Mortensen E, Akinlade B, Braunstein N, Stahl N, Torri A, Davis JD, DiCioccio AT. Kamal MA, et al. Front Immunol. 2024 Nov 11;15:1466372. doi: 10.3389/fimmu.2024.1466372. eCollection 2024. Front Immunol. 2024. PMID: 39588375 Free PMC article.
Iron deficiency anemia in pregnancy and the postpartum: a practical approach by the Italian GOAL Working Group.
Paradisi G, Anelli L, Barletta F, Battaglia FA, Boninfante M, Bonito M, Brunelli R, Carboni F, Carducci B, Cavaliere A, Ciampelli M, DE Matteis G, DE Vita D, Desiato M, DI Cioccio A, DI Iorio R, Ferrazzani S, Lena A, Lippa F, Magliocchetti P, Maneschi F, Marceca M, Marinoni E, Marzilli R, Napolitano V, Nicolanti G, Oliva M, Palazzetti P, Piscicelli C, Ragusa A, Saccucci P, Salerno G, Serra G, Signore F, Spina V, Valensise H, Orabona R, Lanzone A; Italian GOAL Working Group. Paradisi G, et al. Among authors: di cioccio a. Minerva Obstet Gynecol. 2024 Oct;76(5):470-477. doi: 10.23736/S2724-606X.24.05438-1. Minerva Obstet Gynecol. 2024. PMID: 39501893 Free article.
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.
Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, Xiao J, Patel Y, Turner KC, Davis JD, Irvin SC, Pan C, Atmodjo-Watkins D, Hooper AT, Hamilton JD, Subramaniam D, Bocchini JA, Kowal B, DiCioccio AT, Bhore R, Geba GP, Cox E, Braunstein N, Dakin P, Herman GA. Norton TD, et al. BMJ Open. 2024 Oct 8;14(10):e087431. doi: 10.1136/bmjopen-2024-087431. BMJ Open. 2024. PMID: 39384241 Free PMC article. Clinical Trial.
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.
Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, Xiao J, Turner KC, Davis JD, Irvin SC, Pan C, Atmodjo D, Hooper AT, Hamilton JD, Hussein M, Subramaniam D, Roque-Guerrero L, Kohli A, Mylonakis E, Geba GP, Cox E, Braunstein N, Dakin P, Kowal B, Bhore R, DiCioccio AT, Hughes D, Herman GA; Trial Investigators. Norton TD, et al. J Pediatric Infect Dis Soc. 2024 Oct 1:piae105. doi: 10.1093/jpids/piae105. Online ahead of print. J Pediatric Infect Dis Soc. 2024. PMID: 39351798
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
Isa F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, Olenchock BA, Brackin T, Ganguly S, Forleo-Neto E, Faria L, Heirman I, Marovich M, Hutter J, Polakowski L, Irvin SC, Thakur M, Hooper AT, Baum A, Petro CD, Fakih FA, McElrath MJ, De Rosa SC, Cohen KW, Williams LD, Hellman CA, Odeh AJ, Patel AH, Tomaras GD, Geba GP, Kyratsous CA, Musser B, Yancopoulos GD, Herman GA; Trial Working Group. Isa F, et al. Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00421-3. doi: 10.1016/S1473-3099(24)00421-3. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39236733
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C, Forleo-Neto E, Eagan W, Musser BJ, Davis JD, Turner KC, Norton T, Hooper AT, Hamilton JD, Pan C, Mahmood A, Baum A, Kyratsous CA, Kim Y, Parrino J, Kampman W, Roque-Guerrero L, Stoici R, Fatakia A, Soo Y, Geba GP, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM; COVID-19 Phase 2 Dose-Ranging Study Team. Portal-Celhay C, et al. JAMA Netw Open. 2022 Aug 1;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411. JAMA Netw Open. 2022. PMID: 35969402 Free PMC article. Clinical Trial.
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
Somersan-Karakaya S, Mylonakis E, Menon VP, Wells JC, Ali S, Sivapalasingam S, Sun Y, Bhore R, Mei J, Miller J, Cupelli L, Forleo-Neto E, Hooper AT, Hamilton JD, Pan C, Pham V, Zhao Y, Hosain R, Mahmood A, Davis JD, Turner KC, Kim Y, Cook A, Kowal B, Soo Y, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM; COVID-19 Phase 2/3 Hospitalized Trial Team. Somersan-Karakaya S, et al. J Infect Dis. 2022 Dec 28;227(1):23-34. doi: 10.1093/infdis/jiac320. J Infect Dis. 2022. PMID: 35895508 Free PMC article. Clinical Trial.
A drug-disease model for predicting survival in an Ebola outbreak.
Toroghi MK, Al-Huniti N, Davis JD, DiCioccio AT, Rippley R, Baum A, Kyratsous CA, Sivapalasingam S, Kantrowitz J, Kamal MA. Toroghi MK, et al. Clin Transl Sci. 2022 Oct;15(10):2538-2550. doi: 10.1111/cts.13383. Epub 2022 Aug 17. Clin Transl Sci. 2022. PMID: 35895082 Free PMC article.
41 results